Brief: 4Dmt Completes Enrollment For 4Front-1 Phase 3 Clinical Trial Of 4D-150 In Wet AMD
09/02/2026 14:59
Feb 9 (Reuters) - 4D Molecular Therapeutics Inc FDMT.O: 4DMT COMPLETES ENROLLMENT FOR 4FRONT-1 PHASE 3 CLINICAL TRIAL OF 4D-150 IN WET AMD Source text: ID:nGNX2ZHj4m Further company coverage: FDMT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on 4D Molecular Therapeutics
See all news4D Molecular Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
4D Molecular Therapeutics Q2 net loss widens
Brief: 4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview
Brief: 4d Molecular Therapeutics Says 4D-150 Continues To Be Well Tolerated With No New Safety Findings